Results 211 to 220 of about 51,731 (234)

CYP3A5*3 and SLCO1B1 c.521T>C Polymorphisms Influence the Pharmacokinetics of Atorvastatin and 2-Hydroxy Atorvastatin

Pharmaceutics, 2022
Ji-Young Park, Jong-Min Kim, Kyoung-Ah Kim   +2 more
exaly  

Atorvastatin

Reactions Weekly, 2011
openaire   +2 more sources

Atorvastatin

Reactions Weekly, 2013
openaire   +2 more sources

Clinical Pharmacokinetics of Atorvastatin

Clinical Pharmacokinetics, 2012
Hans Lennernäs, Lennernäs Hans
exaly  

Reduction of LDL Cholesterol by 25% to 60% in Patients With Primary Hypercholesterolemia by Atorvastatin, a New HMG-CoA Reductase Inhibitor

Arteriosclerosis, Thrombosis, and Vascular Biology, 1995
Stuart R Weiss, Michael H Davidson, Dennis L Sprecher   +2 more
exaly  

Binding interaction of atorvastatin with bovine serum albumin: Spectroscopic methods and molecular docking

Spectrochimica Acta - Part A: Molecular and Biomolecular Spectroscopy, 2016
Jie-Hua Shi
exaly  

Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial

Lancet, The, 2004
Helen M Colhoun, P N Durrington, Graham A Hitman   +2 more
exaly  

Effect of atorvastatin on glycaemia progression in patients with diabetes: an analysis from the Collaborative Atorvastatin in Diabetes Trial (CARDS)

Diabetologia, 2015
Shona J Livingstone, Helen C Looker, Tahira Akbar   +2 more
exaly  

Amlodipine/Atorvastatin

Drugs, 2012
Monique P Curran, Curran Monique P
exaly  

Efficacy and Safety of Atorvastatin in the Prevention of Cardiovascular End Points in Subjects With Type 2 Diabetes

Diabetes Care, 2006
Michael D’Emden, Stuart J Pocock, Knopp Robert H   +2 more
exaly